Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery
Advanced Science · 29.10.2026
DOI: 10.1002/advs.78568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.10.2026. Verfasst von Ranjit Shaw und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wadhwani Research Center for Bioengineering (WRCB), ANRF-ARG, DST SERB-SUPRA, JC Bose Fellowship.
Abstract (Originalsprache)
Sustained delivery of therapeutic proteins remains a major challenge because rapid degradation and diffusion necessitate frequent dosing, compromising therapeutic efficacy. Here, we present an injectable peptide‐based functional amyloid hydrogel as a versatile drug depot that preserves protein stability while enabling sustained cargo release. As a representative therapeutic application, insulin delivery for diabetes was employed to validate the platform. It exhibited excellent biocompatibility and injectability, providing controlled insulin release over 90 h while preserving its structural stability. Following a single subcutaneous administration in diabetic rats, it restored normoglycemia within 30 min and maintained it for 60 h, followed by a rebound at 66 h, representing a much longer period of glucose maintenance than free insulin. Long‐term in vivo biosafety studies confirmed the absence of systemic toxicity following repeated administration. To demonstrate the tunability of this platform, it was further engineered with sodium alginate as a representative bioadditive, thereby enabling tunable release kinetics and extending sustained insulin release while maintaining injectability and biocompatibility. Collectively, these findings establish peptide‐based functional amyloid hydrogels, either alone or engineered with a bioadditive, as a safe, injectable, and tunable platform for sustained therapeutic delivery, with diabetes serving as a representative proof of concept for broad biomedical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India.
- Sunita Sanghi Center of Aging and Neurodegenerative Diseases (SCAN), Indian Institute of Technology Bombay, Mumbai, India.
ORCID-Profile: Ranjit Shaw, Niyamat M A Chimthanawala, Sadhana Sathaye, Samir K Maji
Förderung
- Wadhwani Research Center for Bioengineering (WRCB), ANRF-ARG
- DST SERB-SUPRA
- JC Bose Fellowship
- TATA Innovation
- DBT
- Sunita Sanghi Center of Aging and Neurodegenerative Diseases (SCAN), IIT Bombay
- Prime Minister's Research Fellowship
- Ministry of Education, Government of India
Zitieren
APA
Shaw, R., Chimthanawala, N. M. A., Manna, S., Sathaye, S., & Maji, S. K. (2026). Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery. Advanced Science. https://doi.org/10.1002/advs.78568
Vancouver
Shaw R, Chimthanawala NMA, Manna S, Sathaye S, Maji SK. Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery. Advanced Science. 2026. doi:10.1002/advs.78568
BibTeX
@article{Shaw2026,
author = {Shaw, Ranjit and Chimthanawala, Niyamat M A and Manna, Shouvik and Sathaye, Sadhana and Maji, Samir K},
title = {Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78568}
}
EUVIMED